Status:
RECRUITING
Meniscal INfiltration of Corticosteroid Guided With Ultra Sonography
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Meniscus Lesion
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The value of corticosteroid infiltration of the meniscus wall in the therapeutic strategy is not clearly defined: the data in the literature on the effectiveness of corticosteroid infiltration are het...
Detailed Description
"Meniscal pain" is a very frequent cause of consultation in orthopedics, rheumatology or sports medicine. The management of degenerative meniscal lesions has been the subject of a consensus conference...
Eligibility Criteria
Inclusion
- Localized knee pain with tenderness over the medial or lateral joint space reproduced on clinical examination
- Pain assessed with a VAS score \> 4/10 despite first-line medical treatment including the use of tier I or II analgesics or NSAIDs.
- An MRI of the knee performed in the 6 months preceding the operation as part of the pre-treatment assessment
- Medial or lateral degenerative meniscal lesion on MRI consistent with pain, confirmed by an investigating physician
- Affiliation to the Social Security
- Free and informed consent signed by the patient
Exclusion
- Patient under curatorship, guardianship or safeguard of justice
- Inability to speak, read or write French fluently
- Patient deprived of liberty
- Patients with psychiatric pathology
- Patient who has had an MRI showing an unstable meniscal lesion: complete vertical tear of more than 10 mm in length, capsulomeniscal disinsertion of more than 10 mm in length, complex tear, T2 hypersignal tear of liquid type with passage of liquid testifying to the spreading of the edges, tear with displaced meniscal fragment, lesion of a posterior meniscal brake, lesion of the meniscotibial or meniscofemoral attachment
- Patient with an MRI showing recent ligament injury(ies) (cruciate ligaments and/or collateral ligaments)
- History of knee trauma less than 3 months
- History of arthroscopy or open surgery of the involved knee,
- History of corticosteroid injection in the knee concerned in the 3 months preceding inclusion,
- Use of NSAIDs and oral corticosteroids during the 48 hours preceding inclusion
- Use of tier 3 analgesics for gonalgia in the 3 months prior to inclusion
- Episodes of knee instability or true locking
- Radiographic gonarthrosis with a Kellgren Lawrence stage \>1 authenticated on radiographic images taken within the last 6 months.
- Known inflammatory rheumatism
- Fibromyalgia as determined by the clinical investigator
- Pregnancy and breastfeeding in progress
- Contraindication to the use of injectable corticosteroids: septic arthritis, skin lesions at the injection site, severe coagulation disorders, hypersensitivity to one of the excipients
- Contraindication to the use of systemic corticosteroids: acute infection, untreated and uncontrolled chronic infection, psychiatric or ophthalmological pathologies, unbalanced diabetes, uncontrolled hypertension
- Contraindication to the use of lidocaine: known hypersensitivity to lidocaine hydrochloride, to local anaesthetics with an amide bond or to one of the excipients, patients with recurrent porphyrias
- Patients on anticoagulants
Key Trial Info
Start Date :
March 6 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2028
Estimated Enrollment :
152 Patients enrolled
Trial Details
Trial ID
NCT06527235
Start Date
March 6 2025
End Date
June 1 2028
Last Update
December 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UHToulouse
Toulouse, France